Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Plantar Psoriasis Associated with Olmesartan

Author(s): Ons Charfi, Talel Badri, Ghozlane Lakhoua, Sarrah Kastalli, Sihem El Aidli and Ahmed Zaïem*

Volume 14, Issue 1, 2019

Page: [77 - 79] Pages: 3

DOI: 10.2174/1574886313666181017120629

Price: $65

Abstract

Background: Psoriasis is a chronic inflammatory skin disorder that may be initiated or exacerbated by some drug intakes. Some of the most common medications known to trigger or worsen existing psoriasis include lithium, gold salts, beta blockers and antimalarials.

Conclusion: We report an exceptional case of plantar psoriasis in a woman who was treated by olmesartan for 3 years.

Keywords: Psoriasis, sartans, antagonist receptors of angiotensin II, olmesartan, side effect, interleukin.

« Previous Next »
Graphical Abstract

[1]
Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3: 121-8.
[2]
Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-75.
[3]
Milavec-Puretić V, Mance M, Ceović R, Lipozenčić J. Drug induced psoriasis. Acta Dermatovenerol Croat 2011; 19: 39-42.
[4]
Perera GK, Di MP, Nestle FO. Psoriasis. Annu Rev Pathol 2012; 7: 385-422.
[5]
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
[6]
Piérard-Franchimont C, Piérard GE. L’iatrogénie psoriasique. Rev Med Liege 2012; 67: 139-42.
[7]
Tsankov N, Irena A, Kasandjieva J. Drug-induced psoriasis: Recognition and management. Am J Clin Dermatol 2000; 1: 159-65.
[8]
Naranjo CA, Busto U, Sellars EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
[9]
Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23-33.
[10]
Puchler K, Lacis P, Gunther A. Safety, tolerability and efficacy of the new oral angiotensin II (AT 1) receptor antagonist CS-866 in patients with mild to moderate hypertension. J Hum Hypertens 1999; 13: 4.
[11]
Torpet LA, Kragelund C, Reibel J, Nauntofte B. Oral adverse reactions to cardiovascular drugs. Crit Rev Oral Biol Med 2004; 5: 28-46.
[12]
Schmutz J-L, Barbaud A, Trechot P. Effets secondaires cutanés des sartans. Ann Dermatol Venereol 2004; 3: 315.
[13]
Marquart-Elbaz C, Grosshans E, Lipsker D, Lipsker D. Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol 2002; 147: 617-8.
[14]
Lamba G, Palaniswamy C, Singh T, Shah D, Lal S, Vinnakota R, et al. Psoriasis Induced by Losartan Therapy: A Case Report and Review of the Literature. Am J Ther 2011; 18: 78-80.
[15]
Fournier B, Boye T, Guennoc B, Carsuzaa F. Psoriasis et sartans : Les mauvais amis. À propos d’une observation. Rev Med Interne 2002; 23: 181s-2s.
[16]
Steckelings UM, Artuc M, Paul M, Stoll M, Henz BM. Angiotensin II stimulates proliferation of primary human keratinocytesviaa non-AT1, non-AT2 angiotensin receptor. Biochem Biophys Res Commun 1996; 229: 329-33.

Rights & Permissions Print Cite
Article Metrics
46
3
1
1
© 2024 Bentham Science Publishers | Privacy Policy